×
ACH slumped -30.00% during the regular session, falling from a prior close of $0.2981 to a latest price of $0.2087. No verified news or fundamental catalyst found. The drop is likely liquidity-driven in this thinly traded post-delisting OTC ADR, which routinely swings by tens of percent per session (typical daily move near 6.7%).
Third-quarter 2026 revenue reached RMB 61.18 billion, up 1.74% year over year. Net profit attributable to shareholders rose 59.10% to RMB 6.04 billion in the quarter, with basic earnings per share of RMB 0.352.
Third Quarter 2026 HIFU (High-Intensity Focused Ultrasound) revenue reached $9.8 million, up 26% from $7.8 million a year earlier. Gross margin improved to 51.4% from 46.6%, a gain of 482 basis points (4.82 percentage points).
Cardinal Health reported first-quarter fiscal 2027 revenue of $67.5 billion , up 5% year over year and ahead of consensus estimates. Non-GAAP diluted EPS (earnings per share) reached $3.26 , up 28% year over year and above analyst expectations; GAAP (Generally Accepted Accounting Principles) diluted EPS rose 27% to $2.38 .
Cencora reported fiscal fourth-quarter revenue of $88.4 billion, up 5.5% year over year and slightly above consensus estimates. Adjusted diluted earnings per share (EPS, or profit per share) reached $4.66, a 21.4% increase and ahead of the roughly $4.56 consensus.
McKesson reported adjusted EPS (earnings per share) of $11.68 for the second quarter of fiscal 2027, up 18% year over year and above the consensus estimate of roughly $10.71. Consolidated revenue rose 8% to approximately $111 billion ($110.96 billion), topping the roughly $109.86 billion analyst consensus.
Major catalysts ahead: Continued execution of the company's 2026 revenue target of more than $90 million, a record contract-manufacturing order book at Cana Laboratories, and a potential European Investment Bank (EIB) financing advisory arrangement for up to €25 million in research and development (R&D) funding. Strategic positioning: A vertically integrated healthcare platform spanning pharmaceutical distribution, European Union (EU)-licensed manufacturing, proprietary nutraceutical brands, and a U.S. direct-to-consumer (DTC) subscription business.
Cosmos Health (COSM) shares fell approximately 10.8% over the past 30 days, from about $0.35 to near $0.31. The decline follows a sharp September rally and reflects the elevated volatility typical of a low-priced microcap stock.
Henry Schein reported third quarter 2026 adjusted earnings per share (EPS) of $1.56 , up 19% year over year and well above the consensus estimate of $1.36. Net sales rose 4.0% to $3.47 billion , though the figure came in slightly below the roughly $3.48 billion analysts had expected.
FocalTherics (FOCL), formerly EDAP TMS, traded near $4.32, a modest gain of roughly 2.9% over the trailing 30 days following its rebrand to a pure-play robotic focal therapy company. The stock has consolidated in a tight range between roughly $4.00 and $4.75, reflecting balanced investor sentiment ahead of a key earnings release.
Upcoming catalyst: The next quarterly earnings report (scheduled around November 5, 2026) will be closely watched for Focal One placement momentum and HIFU revenue tracking against the company's full-year guidance. Strategic repositioning: Management is refocusing on the higher-growth robotic focal therapy business, with HIFU now representing the majority of revenue as the distribution and ESWL segment is reported separately.
FOCL is the Nasdaq-listed American Depositary Receipt (ADR) of EDAP TMS S.A., a French medical technology company doing business as FocalTherics. The company develops non-invasive, energy-based therapeutic ultrasound devices, primarily for urological conditions, including the Focal One robotic HIFU system for treating prostate cancer.
Both CAH and MCK are large-cap U.S. pharmaceutical distribution leaders benefiting from resilient healthcare demand and specialty-drug growth, yet they differ in valuation, momentum, and catalysts. Cardinal Health is expanding higher-margin specialty and physician-services businesses, while McKesson is consolidating its position through large acquisitions and a renewed long-term customer agreement.
CAH , COR , and MCK are the three largest U.S. pharmaceutical distributors, competing on scale, specialty services, and oncology, yet diverging in recent market momentum. Tickeron AI Verdict: CAH — Cardinal Health currently presents the most consistent blend of upward price trend, earnings momentum, and clarity of forward guidance among the three.
Both CAH and COR are among the "big three" U.S. pharmaceutical distributors, yet their recent stock trajectories have diverged sharply. Cardinal Health has delivered stronger recent momentum, with its shares climbing roughly 60% over the trailing year, compared with a single-digit-to-low-teens gain for Cencora over a similar span.
Cardinal Health (CAH) shares climbed roughly 11.3% over the past 30 days, moving from about $228 to near $254. The advance accelerated in early October after the company extended its pharmaceutical distribution agreement with CVS Health through June 30, 2032.
Specialty is the core growth engine. Management expects Specialty revenue to top $50 billion in fiscal 2026, a roughly 16% compound annual growth rate (CAGR) over three years, driven by oncology, urology, and autoimmune platforms. Guidance points to sustained double-digit earnings growth. Cardinal Health is guiding fiscal 2027 adjusted earnings per share (EPS, a measure of profit per share) growth of 13%–15%, above its reconfirmed long-term target of 12%–14%.
Cardinal Health, Inc. ( CAH ) is a global healthcare services and products company headquartered in Dublin, Ohio. The company operates two main reportable segments: Pharmaceutical and Specialty Solutions and Global Medical Products and Distribution (GMPD) , alongside growth businesses in nuclear medicine, at-home solutions, and logistics.
COR (Cencora) and MCK (McKesson) are two of the three dominant U.S. pharmaceutical wholesale distributors, giving both durable scale and defensive cash-flow characteristics. MCK carries the stronger recent momentum, trading near its 52-week high with a roughly 22% year-to-date advance, while COR has cooled after pulling back from its own record level.
Growth catalysts center on the company's ability to deepen its relationships with major Chinese e-commerce platforms (including Tmall, JD.com, Pinduoduo, and Meituan) and expand its merchant base beyond the 300-plus online sellers it served as of early 2026. Strategic positioning is built on a "closed-loop" cross-border supply chain for over-the-counter (OTC) medicines, spanning procurement, customs clearance, drug registration, warehousing, packaging, and last-mile delivery between Hong Kong and Mainland China.